IPM Take
The ADC story is no longer confined to later-line rescue therapy. In lung cancer, the question is becoming whether an ADC can move into the first-line setting and reshape the chemotherapy conversation. But the politics of “chemo replacement” must be handled carefully. A better progression-free survival curve is not enough if toxicity, access, price and sequencing are unresolved.
Executive Summary
ASCO Post reported that an interim analysis of the Chinese Phase III OptiTROP-Lung05 trial, published in The Lancet, showed sacituzumab tirumotecan plus pembrolizumab significantly prolonged progression-free survival compared with pembrolizumab alone in first-line PD-L1-positive advanced NSCLC without targetable genomic alterations. The trial enrolled 413 patients. Median progression-free survival was not reached with the combination versus 5.7 months with pembrolizumab alone, with a hazard ratio of 0.35. Grade 3 or higher adverse events occurred in 55% of patients receiving the combination versus 31% receiving pembrolizumab alone.
Why it matters
- Patients / advocates: A stronger first-line response may matter, but added toxicity cannot be treated as background noise.
- Clinicians: The trial pushes ADC-immunotherapy combinations closer to the first-line NSCLC decision point.
- Regulators: Evidence from China will need careful review for generalisability across wider populations and treatment systems.
- Payers / HTA bodies: ADC combinations raise serious questions on price, duration, toxicity management and comparator choice.
Every few years, oncology declares a new chemotherapy replacement. Most of the time, the story turns out to be more complicated.
The OptiTROP-Lung05 data deserve attention because they are not a small signal. In 413 patients with PD-L1-positive advanced NSCLC without targetable genomic alterations, sacituzumab tirumotecan plus pembrolizumab significantly improved progression-free survival compared with pembrolizumab alone. Median PFS was not reached in the combination arm and was 5.7 months in the pembrolizumab-alone arm. The hazard ratio was 0.35.
That is the kind of result that makes the field sit up.
It is also the kind of result that needs pressure-testing. The study was open-label and conducted in China. The comparator was pembrolizumab alone, not chemo-immunotherapy. The strongest policy and clinical question is not whether the combination beats pembrolizumab alone. It is where ADC-immunotherapy belongs against existing first-line standards across PD-L1 groups, geographies and health systems.
Toxicity also matters. Grade 3 or higher adverse events occurred in 55% of patients receiving sacituzumab tirumotecan plus pembrolizumab versus 31% with pembrolizumab alone. Neutrophil count decreases, anaemia, white blood cell count decreases, pneumonia and stomatitis were among the most common severe events.
So the real question is not “ADC or no ADC.” It is which patients should receive this strategy, against which comparator, at what cost, and with what infrastructure for toxicity management.
The ADC era in lung cancer is no longer theoretical. But if it is going to move into first-line care, it has to bring evidence discipline with it.
